Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125897891 | 12589789 | 1 | I | 201606 | 20160628 | 20160725 | 20160725 | PER | US-SHIRE-US201608194 | SHIRE | 50.75 | YR | F | Y | 74.83000 | KG | 20160725 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125897891 | 12589789 | 1 | PS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 70 MG, 1X/DAY:QD | Y | 21977 | 70 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 2 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | UNK UNK, 1X/DAY:QD (40 MG CAPSULE PLACED IN WATER TOOK HALF GLASS ONCE) | Y | 21977 | CAPSULE | QD | |||||||
| 125897891 | 12589789 | 3 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 40 MG, 1X/DAY:QD (MONDAY THROUGH FRIDAY) | Y | 3140615 | 21977 | 40 | MG | CAPSULE | QD | ||||
| 125897891 | 12589789 | 4 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 30 MG, 1X/DAY:QD | Y | 21977 | 30 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 5 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 40 MG, 1X/DAY:QD | Y | 21977 | 40 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 6 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 50 MG, 1X/DAY:QD | Y | 21977 | 50 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 7 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 60 MG, 1X/DAY:QD | Y | 21977 | 60 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 8 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 30 MG, 1X/DAY:QD | Y | 21977 | 30 | MG | CAPSULE | QD | |||||
| 125897891 | 12589789 | 9 | SS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 1X/DAY:QD, TITRATED FROM 40-60 MG DAILY | Y | 21977 | CAPSULE | ||||||||
| 125897891 | 12589789 | 10 | C | PRAVASTATIN SODIUM. | PRAVASTATIN SODIUM | 1 | Oral | 40 MG, 1X/DAY:QD | 0 | 40 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125897891 | 12589789 | 1 | Attention deficit/hyperactivity disorder |
| 125897891 | 12589789 | 10 | Blood cholesterol increased |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125897891 | 12589789 | Abdominal pain upper | |
| 125897891 | 12589789 | Drug effect increased | |
| 125897891 | 12589789 | Drug ineffective | |
| 125897891 | 12589789 | Incorrect dose administered | |
| 125897891 | 12589789 | Incorrect product storage | |
| 125897891 | 12589789 | Initial insomnia | |
| 125897891 | 12589789 | Muscle twitching | |
| 125897891 | 12589789 | Nervousness | |
| 125897891 | 12589789 | Paranoia | |
| 125897891 | 12589789 | Product quality issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125897891 | 12589789 | 2 | 20160623 | 20160623 | 0 | |
| 125897891 | 12589789 | 3 | 20160624 | 0 | ||
| 125897891 | 12589789 | 4 | 2012 | 0 | ||
| 125897891 | 12589789 | 9 | 2009 | 0 | ||
| 125897891 | 12589789 | 10 | 2005 | 0 |